The Week of May 6 in Review

The week of May 6 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.

Mechanism of Action: Cetuximab

Penny Daugherty Comments on the Presence of a BRCA Mutation

Dr. Piccart on the Changing View of Anti-HER2 Therapies

TweetOla Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for myeloma in 2013.Daniel P. Petrylak, MD, director, Prostate and Genitourinary Cancer Program, co-director, Signal Transduction Research Program, at the Smilow Cancer Center at Yale-New Haven, discusses potential biomarkers currently being explored in castration-resistant prostate cancer (CRPC).Cetuximab is an epidermal growth factor receptor inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer.Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the changing view of anti-HER2 therapies for patients with breast cancer.

Cabozantinib in Medullary Thyroid Cancer

Dr. Howard Scher on Findings From the COU-AA-302 Trial

PI3K Inhibitors in Breast Cancer Treatment

Dr. Zaks Describes the Mechanism of Action of SAR302503

Turning Concept Into Reality: Modulating the Immune System to Treat NSCLC

Dr. Leonard Gomella on Utilizing CTCs in Solid Tumors

Cabozantinib is a novel, small-molecule, multitargeted receptor tyrosine kinase inhibitor with particular activity against MET, VEGFR-2, and RET.Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Prostate and Urologic Cancers at Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial.Aberrant activation of the PI3K pathway occurs frequently in breast cancer and contributes to treatment resistance to standard therapy.Tal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, explains the mechanism of action of SAR302503, a tyrosine kinase inhibitor being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis.For many years non—small cell lung cancer (NSCLC), unlike melanoma and renal cell carcinoma, was thought to be a nonimmunogenic tumor unlikely to benefit from therapies aimed at augmenting endogenous antitumor immunity.